Acceptability and tolerability of a dermocosmetic kit in patients undergoing cancer treatment with dermatological adverse reactions
Aceptabilidad y tolerabilidad de un kit dermocosmético en pacientes en tratamiento oncológico con reacciones adversas dermatológicas
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Show authors biography
Adverse skin reactions secondary to antineoplastic therapy are frequent. For its treatment, in Colombia there is a dermocosmetic kit, which restores and protects the barrier function of the skin. Objective: to describe the experience of use, evolution and quality of life of cancer patients undergoing treatment, with prescription of a dermocosmetic kit. Methods: a descriptive observational study based on medical records was carried out, including patients with cancer in active treatment, who were prescribed a dermocosmetic kit. Sociodemographic data, level of xerosis, functionality and the SKINDEX-29 scale (symptoms and quality of life) were taken from the baseline consultation. From the 7-week follow-up, the clinical evolution and the experience of using the kit were documented. Descriptive analysis of the data was performed. Results: Fifty-nine patients with a diagnosis of cancer undergoing treatment, between the ages of 25 and 89, were included. On a scale of 0 to 10, ease of use, overall satisfaction, and physician satisfaction received a median score of 10. In 91.5% of patients, the level of xerosis was reduced. Pruritus measured from 0 to 100, went from a median of 75 points at the beginning of the follow-up, to a final median of 25 points. 15.3% of the patients had a severe affectation of their quality of life in the baseline measurement, and after 7 weeks of follow-up, this affectation presented in 5.1% of the patients. The most affected domain was symptoms. Conclusions: Ease of use, overall satisfaction, and physician satisfaction with the dermocosmetic kit was excellent. There was an effect in the reduction of xerosis, pruritus and the quality of life of these patients was improved.
Article visits 466 | PDF visits 225
- Fearfield L, Natkunarajah J. Cutaneous Side Effects of Chemotherapy and Radiotherapy. 2016. In: Rook’s Textbook of Dermatology [Internet]. [1-15]. Disponible en: https://dx.doi.org/10.1002/9781118441213.rtd0121
- Hall S, Rudrawar S, Zunk M, Bernaitis N, Arora D, McDermott CM, et al. Protection against Radiotherapy-Induced Toxicity. Antioxidants (Basel). [Internet] 2016;5(3). Disponible en: https://dx.doi.org/10.3390/antiox5030022.
- Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw. [Internet] 2009;7 Suppl 1:S5-21; quiz S2-4. Disponible en: https://dx.doi.org/10.6004/jnccn.2009.0074
- Spalek M. Chronic radiation-induced dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. [Internet] 2016;9:473-82. Disponible en: https://dx.doi.org/10.2147/CCID.S94320
- De Tursi M, Zilli M, Carella C, Auriemma M, Lisco MN, Di Nicola M, et al. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. Onco Targets Ther. [Internet] 2017;10:3007-15. Disponible en: https://dx.doi.org/10.2147/OTT.S127795
- Thanthong S, Nanthong R, Kongwattanakul S, Laebua K, Trirussapanich P, Pitiporn S, et al. Prophylaxis of Radiation-Induced Dermatitis in Patients With Breast Cancer Using Herbal Creams: A Prospective Randomized Controlled Trial. Integr Cancer Ther. [Internet] 2020;19:1534735420920714. Disponible en: https://dx.doi.org/10.1177/1534735420920714
- Fabbrocini G, Cameli N, Romano MC, Mariano M, Panariello L, Bianca D, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res. [Internet] 2012;31:50. Disponible en: https://dx.doi.org/10.1186/1756-9966-31-50
- Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. [Internet] 2009;4(2):107-19. Disponible en: https://dx.doi.org/10.1007/s11523-009-0114-0
- Sauder MB, Addona M, Andriessen A, Butler M, Claveau J, Feugas N, et al. The Role of Skin Care in Oncology Patients [Internet] 2020:[1-12 pp.]. Disponible en: https://www.skintherapyletter.com/wp-content/uploads/2020/12/STL-Supp-SkinCareOnc-v2-correction.pdf.
- Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. [Internet] 2010;28(8):1351-7. Disponible en: https://dx.doi.org/10.1200/JCO.2008.21.7828
- Long V, Choi EC, Tan CL. Supportive oncodermatology-a narrative review of its utility and the way forward. Support Care Cancer. [Internet] 2021;29(9):4931-7. Disponible en: https://dx.doi.org/10.1007/s00520-021-06124-w
- Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Crit Rev Oncol Hematol. [Internet] 2015;96(1):167-82. Disponible en: https://dx.doi.org/10.1016/j.critrevonc.2015.06.001
- Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. [Internet] 2011;16(2):228-38. Disponible en: https://dx.doi.org/10.1634/theoncologist.2010-0298
- Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, et al. Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel. Cancer Manag Res. [Internet] 2013;5:401-8. Disponible en: https://dx.doi.org/10.2147/CMAR.S52256
- Dreno B, Bensadoun RJ, Humbert P, Krutmann J, Luger T, Triller R, et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol. [Internet] 2013;27(9):1071-80. Disponible en: https://dx.doi.org/10.1111/jdv.12082
- Lüftner D, Dell'Acqua V, Selle F, Khalil A, Leonardi MC, De La Torre Tomás A, et al. Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. Onco Targets Ther. [Internet] 2018;11:5865-72. Disponible en: https://dx.doi.org/10.2147/OTT.S155438
- Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncology. [internet] 2015;11(4):617-27. Disponible en: https://dx.doi.org/https://doi.org/10.2217/fon.14.251
- Berger A, Regueiro C, Hijal T, Pasquier D, De La Fuente C, Le Tinier F, et al. Interest of Supportive and Barrier Protective Skin Care Products in the Daily Prevention and Treatment of Cutaneous Toxicity During Radiotherapy for Breast Cancer. Breast Cancer (Auckl). [Internet] 2018;12:1178223417752772. Disponible en: https://dx.doi.org/10.1177/1178223417752772
- Kalekhan F, Kudva AK, Raghu SV, Rao S, Hegde SK, Simon P, et al. Traditionally Used Natural Products in Preventing Ionizing Radiation-Induced. Anticancer Agents Med Chem. [Internet] 2022;22(1):64-82. Disponible en: https://dx.doi.org/10.2174/1871520621666210405093236
- Kondziołka J, Wilczyński S. Overview of the Active Ingredients in Cosmetic Products for the Care of Skin That Has Been Exposed to Ionizing Radiation - Analysis of Their Effectiveness in Breast Cancer Radiotherapy. Clin Cosmet Investig Dermatol. [Internet] 2021;14:1065-76. Disponible en: https://dx.doi.org/10.2147/CCID.S322228
- Titeca G, Poot F, Cassart D, Defays B, Pirard D, Comas M, et al. Impact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiotherapy: an initial randomized controlled study. J Eur Acad Dermatol Venereol. [Internet] 2007;21(6):771-6. Disponible en: https://dx.doi.org/10.1111/j.1468-3083.2006.02080.x
- Aizman L, Nelson K, Sparks AD, Friedman AJ. The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey. J Drugs Dermatol. [Internet] 2020;19(5):477-82. Disponible en: https://dx.doi.org/10.36849/JDD.2020.5040
- Uysal B, Gamsız H, Dincoglan F, Demiral S, Sager O, Dirican B, et al. Comparative Evaluation of Topical Corticosteroid and Moisturizer in the Prevention of Radiodermatitis in Breast Cancer Radiotherapy. Indian J Dermatol. [Internet] 2020;65(4):279-83. Disponible en: https://dx.doi.org/10.4103/ijd.IJD_607_18.
- Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer. [Internet] 2008;7(1):48-54. Disponible en: https://dx.doi.org/10.3816/CCC.2008.n.007
- Varvaresou A, Iakovou K, Mellou F, Myrogiannis D, Papageorgiou S. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management. J Cosmet Dermatol. [Internet] 2020;19(4):782-8. Disponible en: https://dx.doi.org/10.1111/jocd.13211